FierceBiotechOriginal article
{"a":[{"_":"BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer","$":{"href":"/biotech/brainchild-bio-masterminds-116m-series-pivotal-push-pediatric-brain-cancer","hreflang":"en"}}]}
Positive
AI Analysis
Summary
BrainChild Bio, a startup from Seattle Children's Hospital, raised $116 million in Series A funding to advance CAR-T cell therapies for pediatric brain cancer treatment.
Importance:6/10
Sentiment:
0.70
Series ACAR-Tpediatric oncologycell therapyfinancing
Related Companies
Read the original article
Published by FierceBiotech on September 7, 2026 2:07 PM
